Cargando…
Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study
BACKGROUND: Poststroke depression can lead to functional dependence, cognitive impairment and reduced quality of life. The aim of this study was to evaluate the effects of a percutaneous mastoid electrical stimulator (PMES) plus antidepressants on poststroke depression and cognitive function. METHOD...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257192/ https://www.ncbi.nlm.nih.gov/pubmed/32471373 http://dx.doi.org/10.1186/s12883-020-01795-0 |
_version_ | 1783540043810340864 |
---|---|
author | Lu, Taoli He, Lanying Zhang, Bei Wang, Jian Zhang, Lili Dong, Wei Wei Yang, Hao |
author_facet | Lu, Taoli He, Lanying Zhang, Bei Wang, Jian Zhang, Lili Dong, Wei Wei Yang, Hao |
author_sort | Lu, Taoli |
collection | PubMed |
description | BACKGROUND: Poststroke depression can lead to functional dependence, cognitive impairment and reduced quality of life. The aim of this study was to evaluate the effects of a percutaneous mastoid electrical stimulator (PMES) plus antidepressants on poststroke depression and cognitive function. METHODS: This study was a prospective, randomized, double-blind, and sham-controlled study. A total of 258 clinically depressed ischaemic stroke patients within 14 days of index stroke were randomly assigned to the PMES plus antidepressant (PMES group, N = 125) and sham plus antidepressant (sham group, N = 133) groups. All patients underwent the Montreal Cognitive Assessment (MoCA) and Hamilton Rating Scale for Depression (HRSD) test at 2 weeks (baseline), and 6 months(M6) after ischaemic stroke. Primary outcomes were the percentage of patients showing a treatment response (≥50% reduction in HRSD score) and depression remission (HRSD score ≤ 9) at 6 months. The secondary outcome was the percentage of patients with a MoCA score < 26. RESULTS: The percentages of patients showing a treatment response and depression remission were significantly higher in the PMES group than in the sham group (57.60% vs 41.35%, P = 0.009; 44.00% vs 29.32%, P = 0.014 respectively). The mean value of the HRSD score change [M (month)6-baseline] was significantly higher in the PMES group than in the sham group at 6 months (− 11.93 ± 5.32 vs − 10.48 ± 6.10, P = 0.036, respectively). The percentage of patients with MoCA scores < 26 was lower in the PEMS group than in the sham group (12.0% vs 24.06%, P = 0.012,respectively), and the mean value of the MoCA score change (M6-baseline) was higher in the PMES group than in the sham group (3.50 ± 2.55 vs 2.72 ± 2.52, P = 0.005, respectively). CONCLUSION: These findings demonstrate that PMES adjunctive to antidepressant therapy is effective in reducing depression, achieving remission in the short term, and improving cognition. TRIAL REGISTRATION: This trial was retrospectively registered (registration number: ChiCTR1800016463) on 03 June 2018. |
format | Online Article Text |
id | pubmed-7257192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72571922020-06-07 Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study Lu, Taoli He, Lanying Zhang, Bei Wang, Jian Zhang, Lili Dong, Wei Wei Yang, Hao BMC Neurol Research Article BACKGROUND: Poststroke depression can lead to functional dependence, cognitive impairment and reduced quality of life. The aim of this study was to evaluate the effects of a percutaneous mastoid electrical stimulator (PMES) plus antidepressants on poststroke depression and cognitive function. METHODS: This study was a prospective, randomized, double-blind, and sham-controlled study. A total of 258 clinically depressed ischaemic stroke patients within 14 days of index stroke were randomly assigned to the PMES plus antidepressant (PMES group, N = 125) and sham plus antidepressant (sham group, N = 133) groups. All patients underwent the Montreal Cognitive Assessment (MoCA) and Hamilton Rating Scale for Depression (HRSD) test at 2 weeks (baseline), and 6 months(M6) after ischaemic stroke. Primary outcomes were the percentage of patients showing a treatment response (≥50% reduction in HRSD score) and depression remission (HRSD score ≤ 9) at 6 months. The secondary outcome was the percentage of patients with a MoCA score < 26. RESULTS: The percentages of patients showing a treatment response and depression remission were significantly higher in the PMES group than in the sham group (57.60% vs 41.35%, P = 0.009; 44.00% vs 29.32%, P = 0.014 respectively). The mean value of the HRSD score change [M (month)6-baseline] was significantly higher in the PMES group than in the sham group at 6 months (− 11.93 ± 5.32 vs − 10.48 ± 6.10, P = 0.036, respectively). The percentage of patients with MoCA scores < 26 was lower in the PEMS group than in the sham group (12.0% vs 24.06%, P = 0.012,respectively), and the mean value of the MoCA score change (M6-baseline) was higher in the PMES group than in the sham group (3.50 ± 2.55 vs 2.72 ± 2.52, P = 0.005, respectively). CONCLUSION: These findings demonstrate that PMES adjunctive to antidepressant therapy is effective in reducing depression, achieving remission in the short term, and improving cognition. TRIAL REGISTRATION: This trial was retrospectively registered (registration number: ChiCTR1800016463) on 03 June 2018. BioMed Central 2020-05-29 /pmc/articles/PMC7257192/ /pubmed/32471373 http://dx.doi.org/10.1186/s12883-020-01795-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Lu, Taoli He, Lanying Zhang, Bei Wang, Jian Zhang, Lili Dong, Wei Wei Yang, Hao Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study |
title | Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study |
title_full | Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study |
title_fullStr | Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study |
title_full_unstemmed | Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study |
title_short | Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study |
title_sort | percutaneous mastoid electrical stimulator improves poststroke depression and cognitive function in patients with ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257192/ https://www.ncbi.nlm.nih.gov/pubmed/32471373 http://dx.doi.org/10.1186/s12883-020-01795-0 |
work_keys_str_mv | AT lutaoli percutaneousmastoidelectricalstimulatorimprovespoststrokedepressionandcognitivefunctioninpatientswithischaemicstrokeaprospectiverandomizeddoubleblindandshamcontrolledstudy AT helanying percutaneousmastoidelectricalstimulatorimprovespoststrokedepressionandcognitivefunctioninpatientswithischaemicstrokeaprospectiverandomizeddoubleblindandshamcontrolledstudy AT zhangbei percutaneousmastoidelectricalstimulatorimprovespoststrokedepressionandcognitivefunctioninpatientswithischaemicstrokeaprospectiverandomizeddoubleblindandshamcontrolledstudy AT wangjian percutaneousmastoidelectricalstimulatorimprovespoststrokedepressionandcognitivefunctioninpatientswithischaemicstrokeaprospectiverandomizeddoubleblindandshamcontrolledstudy AT zhanglili percutaneousmastoidelectricalstimulatorimprovespoststrokedepressionandcognitivefunctioninpatientswithischaemicstrokeaprospectiverandomizeddoubleblindandshamcontrolledstudy AT dongweiwei percutaneousmastoidelectricalstimulatorimprovespoststrokedepressionandcognitivefunctioninpatientswithischaemicstrokeaprospectiverandomizeddoubleblindandshamcontrolledstudy AT yanghao percutaneousmastoidelectricalstimulatorimprovespoststrokedepressionandcognitivefunctioninpatientswithischaemicstrokeaprospectiverandomizeddoubleblindandshamcontrolledstudy |